City

Clinical trials near Cincinnati, United States

Active studies with a listed research site in Cincinnati, United States.

27active studies

10recruiting now

10countries represented

140largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 2

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Obesity, OverweightCondition

LY3305677, LY3841136Treatment

Argentina, United States56 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT06143956See eligibility →

Recruiting nowPhase 3

A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

Obesity, Overweight and/or ObesityCondition

PF-08653944, PlaceboTreatment

Brazil, Canada50 locations

PfizerSponsor

Updated 2026-09-04 · NCT07595549See eligibility →

Recruiting nowPhase 3

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

Obesity, OverweightCondition

Maridebart cafraglutide, PlaceboTreatment

Australia, Japan87 locations

AmgenSponsor

Updated 2026-09-03 · NCT07684235See eligibility →

Recruiting nowPhase 2

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

Obesity, OverweightCondition

ABBV-295, PlaceboTreatment

Puerto Rico, United States38 locations

AbbVieSponsor

Updated 2026-09-03 · NCT07752979See eligibility →

Recruiting nowPhase 3

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

Obesity, OverweightCondition

Maridebart Cafraglutide, PlaceboTreatment

Japan, Puerto Rico37 locations

AmgenSponsor

Updated 2026-09-03 · NCT07684144See eligibility →

Recruiting nowPhase 2

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

B-cell Acute Lymphoblastic Leukemia, ObesityCondition

IDEAL2 InterventionTreatment

United States16 locations

Etan OrgelSponsor

Updated 2026-08-19 · NCT05082519See eligibility →

Recruiting nowPhase 2

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

Overweight, ObesityCondition

Macupatide, EloralintideTreatment

United States40 locations

Eli Lilly and CompanySponsor

Updated 2026-08-06 · NCT07589608See eligibility →

Recruiting nowPhase 1

A Single and Multiple Ascending Dose Study of HM17321 in Healthy and Obese Participants

Obesity, ObeseCondition

HM17321, Placebo of HM17321Treatment

United States1 locations

Hanmi Pharmaceutical Company LimitedSponsor

Updated 2026-05-04 · NCT07219589See eligibility →

Recruiting nowNot applicable

Effects of Exercise on Lipids and Endothelial Function in Youth

Obesity & OverweightCondition

Exercise ProgramTreatment

United States1 locations

Children's Hospital Medical Center, CincinnatiSponsor

Updated 2026-02-13 · NCT07409064See eligibility →

Recruiting nowPhase 2

A Novel Obesity Prevention Program for High-Risk Infants in Primary Care

Obesity, Obesity, ChildhoodCondition

THRIVE 2.0Treatment

United States1 locations

Children's Hospital Medical Center, CincinnatiSponsor

Updated 2025-03-05 · NCT06028113See eligibility →

Opening soonPhase 2

A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event

Atherosclerosis, Cardiovascular DiseaseCondition

Clazakizumab, PlaceboTreatment

Argentina, Japan47 locations

Eli Lilly and CompanySponsor

Updated 2026-08-25 · NCT07783802See eligibility →

Opening soonPhase 4

Semaglutide in Youth With Autism Spectrum Disorder

Autism Spectrum Disorder, ObesityCondition

Glucagon-like peptide-1 receptor agonist：Semaglutide, Lifestyle Management (LSM) CounselingTreatment

United States1 locations

Children's Hospital Medical Center, CincinnatiSponsor

Updated 2026-08-18 · NCT07770152See eligibility →

Opening soonPhase 2

GLP-1 RA for Stage 1 Type 1 Diabetes

Stage 1 Diabetes Mellitus, Type 1Condition

Semaglutide, PlaceboTreatment

United States1 locations

Children's Hospital Medical Center, CincinnatiSponsor

Updated 2026-02-24 · NCT07430332See eligibility →

Invitation onlyNot applicable

Healthy Eating for My Infant: A Community- Informed Infant Obesity Prevention Program Addressing the Impact of Maternal Mental Health on Eating and Feeding

Obesity & OverweightCondition

Healthy Eating for My Infant (HEMI)Treatment

United States1 locations

University of CincinnatiSponsor

Updated 2026-06-11 · NCT07284108See eligibility →

Invitation onlyNot applicable

GLP_1 RA Ultrasound Study

Glucagon Like Peptide-1 (GLP-1, Delayed Gastric EmptyingCondition

Glucagon-Like Peptide-1 receptor agonists, Point of Care Gastric UltrasoundTreatment

United States1 locations

Children's Hospital Medical Center, CincinnatiSponsor

Updated 2024-11-07 · NCT06581120See eligibility →

Active, not recruitingPhase 2

A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation

ObesityCondition

Trevogrumab-Part A, Trevogrumab-Part B and Part CTreatment

Puerto Rico, United States60 locations

Regeneron PharmaceuticalsSponsor

Updated 2026-09-01 · NCT06299098See eligibility →

Active, not recruitingPhase 2

Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)

Overweight, Type 2 DiabetesCondition

Petrelintide, PlaceboTreatment

United States48 locations

Zealand PharmaSponsor

Updated 2026-08-21 · NCT06926842See eligibility →

Active, not recruitingPhase 2

A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Obesity, OverweightCondition

LY3841136, TirzepatideTreatment

Argentina, United States52 locations

Eli Lilly and CompanySponsor

Updated 2026-07-17 · NCT06603571See eligibility →

Active, not recruitingPhase 2

MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial

Adult Obesity, Weight ManagementCondition

ECC4703, PlaceboTreatment

United States15 locations

EccogeneSponsor

Updated 2026-06-25 · NCT07505303See eligibility →

Active, not recruitingPhase 1

A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity

Obese But Otherwise Healthy ParticipantsCondition

CRB-913, PlaceboTreatment

United States15 locations

Corbus Pharmaceuticals Inc.Sponsor

Updated 2026-05-29 · NCT07310901See eligibility →

Active, not recruitingPhase 1

Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants

ObesityCondition

BMF-650Treatment

United States1 locations

Biomea Fusion Inc.Sponsor

Updated 2026-04-09 · NCT07223216See eligibility →

Active, not recruitingPhase 3

VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)

Weight LossCondition

VK2735Treatment

Puerto Rico, United States127 locations

Viking Therapeutics, Inc.Sponsor

Updated 2026-04-07 · NCT07104383See eligibility →

Active, not recruitingPhase 4

Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)

ObesityCondition

Naltrexone-Bupropion (NB) Combination, PlaceboTreatment

United States140 locations

Currax PharmaceuticalsSponsor

Updated 2026-03-31 · NCT06098079See eligibility →

Active, not recruitingPhase 4

Surgical or Medical Treatment

Diabetes Mellitus, Type 2, Pediatric ObesityCondition

Advanced Medical Therapy and Bariatric Surgery, Advanced Medical TherapyTreatment

United States3 locations

Children's Hospital Medical Center, CincinnatiSponsor

Updated 2026-03-24 · NCT04128995See eligibility →

Active, not recruitingPhase 2

A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity

Type 2 Diabetes, ObesityCondition

Tirzepatide, PlaceboTreatment

Argentina, Mexico40 locations

Eli Lilly and CompanySponsor

Updated 2026-03-23 · NCT06037252See eligibility →

Active, not recruitingPhase 3

VK2735 for Weight Management Phase 3

Weight LossCondition

VK2735Treatment

Puerto Rico, United States137 locations

Viking Therapeutics, Inc.Sponsor

Updated 2025-11-24 · NCT07104500See eligibility →

Active, not recruitingNot applicable

Early Intervention in Cognitive Aging

Overweight, Obesity and Other Hyperalimentation (E65-E68)Condition

Berry fruit powder OR nutritional ketosis, Placebo powder OR higher carbohydrateTreatment

United States1 locations

University of CincinnatiSponsor

Updated 2025-04-01 · NCT02751866See eligibility →

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.

Clinical trials near Cincinnati, United States

Current studies

Related cities